Stockreport

CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com
PDF -Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study--Expansion cohort in head and neck squamous cell carcinoma added based on observed clinica [Read more]